QSBS in North Carolina: SB 595 Updates Conformity to OBBBA, 3.99% Flat Rate, and What RTP Biotech and Charlotte Fintech Founders Need to Know

North Carolina's conformity to Section 1202: SB 595 and the July 5, 2025 static date

North Carolina uses static conformity to the Internal Revenue Code — rather than automatically adopting each federal tax change as it occurs, the state defines "Code" as the IRC in effect on a particular reference date. Legislation must advance that date each session to capture new federal provisions. Before SB 595, North Carolina's IRC conformity date was January 1, 2023 — a date that predated the One Big Beautiful Bill Act's July 4, 2025 enactment by more than two years, meaning the OBBBA's §1202 enhancements had not yet been incorporated into North Carolina law.¹

SB 595, signed by Governor Josh Stein on July 2, 2026, advanced North Carolina's static conformity date to July 5, 2025 — the day after the OBBBA's enactment. The result is that North Carolina's individual income tax law now incorporates the OBBBA's §1202 amendments for stock issued on or after July 4, 2025:

• Exclusion cap: raised from the greater of $10M or 10× adjusted basis to the greater of $15M or 10× adjusted basis, for stock issued after July 4, 2025
• Tiered exclusion schedule: for post-OBBBA stock — 50% exclusion at a 3-year hold, 75% at a 4-year hold, 100% at a 5-year hold (replacing the pre-OBBBA all-or-nothing 5-year cliff)
• Gross assets threshold: raised from $50M to $75M for stock issued after July 4, 2025

Pre-OBBBA stock (issued before July 4, 2025) continues under the original §1202 rules: a 5-year hold is required for 100% exclusion, the cap is the greater of $10M or 10× adjusted basis, and the gross assets test used a $50M threshold at issuance. North Carolina's prior conformity date (January 1, 2023) captured the pre-OBBBA §1202 rules, which have been in effect since 2010. The SB 595 update adds the OBBBA layer on top.

For the full OBBBA §1202 breakdown — including the 28% rate trap on the non-excluded portion of gain at the 3- and 4-year OBBBA tiers — see the OBBBA QSBS guide. For holding period clock rules (how the clock starts for ISOs, RSAs, SAFEs, and convertible notes), see the holding period guide.

North Carolina's 3.99% flat rate and what Section 1202 saves NC founders

For 2026, North Carolina imposes a flat individual income tax rate of 3.99% on all taxable income — there are no income brackets, no graduated rate schedule, and no preferential long-term capital gains rate.² Every dollar of capital gain, including the non-excluded portion of QSBS gain, is taxed at 3.99%.

The §1202 exclusion eliminates North Carolina income tax entirely on the excluded portion of gain:

• Pre-OBBBA $10M qualifying exit (5-year hold): NC state tax savings ≈ $10M × 3.99% = $399,000
• Post-OBBBA $15M qualifying exit (5-year hold): NC state tax savings ≈ $15M × 3.99% = $598,500

These amounts stack on top of the federal tax eliminated by the exclusion. Federal LTCG at 20% plus NIIT at 3.8% on a fully excluded $15 million gain amounts to approximately $3,570,000 in federal tax eliminated at the 5-year mark. The combined federal-plus-NC benefit on a $15M post-OBBBA qualifying exit exceeds $4.1 million in total tax eliminated for a North Carolina-domiciled founder.

North Carolina cities and counties do not levy a personal income tax. Charlotte, Raleigh, Durham, Cary, and all other North Carolina municipalities impose property taxes and local business license fees but no local wage or income tax on individuals. A North Carolina founder's state-and-local income tax burden on QSBS gains consists entirely of the 3.99% flat state rate.

Scheduled rate reductions: 3.49% in 2027 and beyond

North Carolina's income tax rate is on a legislated glide path downward. Under SB 257 (enacted 2023), the flat rate drops from 3.99% in 2026 to 3.49% in 2027–2029, 3.24% in 2030–2032, and 2.99% beginning in 2033, with potential for two additional 0.25% cuts through 2040 if revenue targets are met.² For QSBS planning purposes, the rate trajectory matters at the margin — but the dominant variable is the federal holding period clock and the §1202 exclusion, not the difference between a 3.99% and 3.49% state rate. Waiting an extra year primarily to capture the 0.5% state rate drop saves approximately $75,000 in state tax on a $15M exit — less than 2% of the combined federal-plus-state savings from the §1202 exclusion itself. Do not let future state rate cuts drive holding period decisions; let the §1202 5-year clock drive them.

North Carolina QSBS worked examples

Research Triangle pharma and biotech: the §1202(e)(3)(A) health-exclusion analysis

The Research Triangle — encompassing Raleigh, Durham, and Chapel Hill — is one of the most concentrated life sciences ecosystems in the United States. Research Triangle Park (RTP) hosts more than 300 life science companies, with over 675 across the broader Triangle region, anchored by Duke University, UNC-Chapel Hill, and NC State University. The Triangle's pharma and biotech concentration (Biogen, Novartis, Pfizer research facilities, and hundreds of clinical-stage biotechs) creates a §1202(e)(3)(A) analysis that every RTP-area founder must understand.³

IRC §1202(e)(3)(A) excludes businesses "in the field of health" from the qualified trade or business definition — specifically businesses where the principal asset is "the reputation or skill of 1 or more of its employees." The statutory language is aimed at personal-service health practices (physician practices, dental groups, behavioral health clinics) where the business's value is inseparable from the professionals rendering care. Drug development companies, medical device manufacturers, and health technology product companies are not excluded by the health-field provision — but the distinction matters enormously in a sector as large and varied as the Triangle's life sciences community.

Pharma and biotech R&D companies: generally qualified

Pharmaceutical companies engaged in drug discovery and development — identifying compounds, conducting preclinical and clinical trials, and seeking FDA approval for therapies — generally do not operate "in the field of health" as §1202(e)(3)(A) uses that phrase. The company's value is in its intellectual property, drug candidates, trial data, and regulatory pathway, not the reputation of individual employees. A clinical-stage biotech with a Phase 2 candidate in oncology or rare disease, incorporated as a Delaware C corporation (common in RTP through NC's Business Court system), and with gross assets below $75M at the time of stock issuance, is paradigmatically a §1202-eligible business. This analysis covers:

• Oncology biotechs, rare-disease drug developers, gene therapy companies
• Contract development and manufacturing organizations (CDMOs) that manufacture drug products (not primarily health services)
• Computational biology and AI drug discovery platforms selling licensed software or discovery partnerships
• Agri-biotech and industrial biotech companies (§1202(e)(3)(D) farming exclusion is the relevant risk, not the health exclusion)

Health services and diagnostics: excluded

Businesses that provide health services directly to patients or health systems are excluded under §1202(e)(3)(A), regardless of technology deployment:

• Telemedicine platforms and digital health companies whose revenue comes from patient clinical visits — whether provider-employed clinicians deliver care digitally or in-person, the business is still in the field of health if clinical services are the primary value
• Revenue cycle management, medical billing, and insurance coding companies where skilled employees' coding expertise is the principal asset
• Behavioral health and mental health service companies (platform or otherwise) where licensed clinicians render patient care
• Home health and skilled nursing operators — even if technology-enabled

Health IT and medical devices: product-versus-services analysis

Software and device companies serving the health care market occupy a gray zone that requires factual analysis:

• Medical device manufacturers: Companies that design, manufacture, and sell FDA-cleared Class II or III devices — surgical instruments, imaging equipment, monitoring devices, diagnostic equipment — are primarily manufacturers and generally are not in the field of health under §1202(e)(3)(A). The PLR 202125004 guidance on Medical Alley device manufacturers (applied in the Minnesota context) extends to RTP-area device companies operating on the same business model.
• Clinical decision support (CDS) software: Companies that sell licensed software to hospitals and health systems for workflow, decision support, or analytics — where the value is in the licensed software product, not in clinical judgment provided by company employees — are generally in technology rather than health services.
• Diagnostics and lab services: A company that develops a novel diagnostic assay or test technology and sells the test as a product (kit, reagent, analyzer) is generally not excluded. A company that operates a reference laboratory and earns revenue by performing diagnostic tests for individual patients as a CLIA-certified clinical laboratory may be closer to health services.
• Mixed revenue models: Companies that combine a software platform with significant clinical services components — concierge care management, population health programs with embedded care coordinators, or payer-funded care management services — need a fact-specific §1202(e)(3)(A) legal opinion based on revenue mix, what the company's principal value-creating assets are, and how IRS guidance and PLR precedent apply to the specific model. See the excluded industries guide for the full statutory framework.

Charlotte fintech: the §1202(e)(3)(B) banking and financing exclusion analysis

Charlotte is the second-largest banking center in the United States by deposits (after New York) and home to the headquarters of Bank of America, the major operations of Wells Fargo, and a growing ecosystem of fintech startups. Charlotte ranked as a top-10 global fintech ecosystem in 2026, with more than 50,000 tech workers in the metro and companies including nCino, LendingTree, AvidXchange, and dozens of venture-backed payments, lending, and financial infrastructure startups.³

IRC §1202(e)(3)(B) excludes businesses "in the field of banking, insurance, financing, leasing, investing, or similar financial services" from qualified trade or business status. Charlotte's fintech concentration creates a §1202(e)(3)(B) risk that does not arise in most startup markets.

Financial software and infrastructure companies: generally qualified

Fintech companies that build and sell software — rather than directly performing financial services — are generally not excluded under §1202(e)(3)(B):

• Banking software and infrastructure: Companies that sell core banking software, cloud banking platforms, lending origination systems, or compliance tools to financial institutions as licensed software products — nCino's model (cloud banking on Salesforce) is illustrative. The company is in the software business; its customers are in banking. §1202(e)(3)(B) excludes the banking field, not the companies that supply technology to banks.
• Payments infrastructure: Companies building payment rails, payment processing APIs, merchant acquiring technology, or ACH/wire automation software — where the company's revenue is from software licensing, SaaS subscriptions, or per-transaction technology fees — are generally in the technology business, not the financing or banking field.
• RegTech and compliance software: Companies that sell AML, KYC, fraud detection, or compliance software to financial institutions are in the software field for §1202 purposes, not the banking or financial services field.

Financial services companies: excluded

Charlotte fintech companies that primarily operate as licensed financial services businesses are excluded under §1202(e)(3)(B), even if heavily technology-enabled:

• Online lenders and mortgage companies that originate, fund, and hold or sell loans — LendingTree's marketplace model sources loans from third-party lenders, but a startup that itself originates and funds consumer or business loans is in the financing field.
• Investment advisers, broker-dealers, and robo-advisers that manage customer assets as their primary business model — regardless of how automated the advice-delivery is.
• Insurance carriers, managing general agents (MGAs), and insurance fronting companies.
• Companies that primarily earn revenue from interest rate spread, loan origination fees, or asset management fees on assets under management — where the primary value is financial intermediation rather than software.

The gray area: embedded finance and marketplace models

Charlotte's fintech landscape includes a number of companies in structurally ambiguous positions for §1202(e)(3)(B):

• Embedded finance infrastructure companies that enable non-financial companies to offer financial products — whether the infrastructure provider is in the financial services field or the software field depends on whether the provider itself holds financial risk, is itself licensed as a financial institution, and whether the principal asset is the software or the financial capacity.
• Marketplace lending platforms that connect borrowers and lenders — if the platform itself does not take on credit risk and earns technology fees, the §1202(e)(3)(B) analysis favors qualification; if the company bears principal credit risk or holds a lending license as a primary operating capacity, the analysis runs the other way.
• Buy-now-pay-later (BNPL) and point-of-sale financing companies where the company provides credit to consumers as part of its core product — even if delivered through a software interface — may be characterized as financing companies under §1202(e)(3)(B).

Charlotte fintech founders in any of these gray areas need a §1202(e)(3)(B) legal opinion from counsel experienced in both tax and financial services licensing before planning around the exclusion. The opinion should address whether the company's principal activity is software/technology or financial services, and whether the company is licensed or regulated in a way that signals financial-services classification. See the excluded industries guide.

North Carolina versus peer startup states: QSBS comparison

North Carolina's 3.99% flat rate is low by comparison to Virginia (5.75%) and New York (10.9%+ with NYC), but higher than zero-tax states like Texas and Florida. For NC-domiciled founders, the combination of full OBBBA §1202 conformity with a relatively low flat rate and no local income taxes makes North Carolina substantially more favorable than California or Pennsylvania for QSBS planning — and comparable to other conforming mid-rate states like Virginia and Illinois.

Planning priorities for North Carolina founders

1. Resolve the §1202(e)(3) question if your company is in life sciences or fintech

NC's clean §1202 conformity only matters if the company's stock passes the qualified-trade-or-business test. For RTP life sciences founders, §1202(e)(3)(A)'s health-exclusion analysis is the primary risk — distinguish pharma/biotech R&D (generally qualifying) from clinical care delivery (generally excluded). For Charlotte fintech founders, §1202(e)(3)(B)'s banking/financing exclusion is the risk — distinguish financial software (generally qualifying) from licensed financial services (generally excluded). Get a written §1202(e)(3) opinion from counsel before planning around gifting, trust structures, or holding period optimization if your company operates in either of these sectors. See the excluded industries guide.

2. Verify all eight qualification tests at issuance, not at sale

The §1202 exclusion depends on facts at issuance — not at sale. C corporation status, gross assets below $50M (pre-OBBBA) or $75M (post-OBBBA) at issuance, the active-business test, original issuance, and eligible-shareholder status must all have been satisfied when you received your shares. RTP biotech founders whose companies took on significant NIH grants, venture capital, or partnership payments before series A may approach the $75M gross assets threshold faster than expected — model this before assuming qualification. NC State and UNC spinouts need to confirm the original-issuance requirement if shares were issued as part of a university license agreement. See the Section 1202 checklist.

3. Reach the 5-year mark for post-OBBBA stock before selling

For stock issued after July 4, 2025, NC's SB 595 conformity date captures the OBBBA tiered exclusion schedule. At a 4-year hold, the non-excluded 25% is taxed at the federal 28% rate plus NC at 3.99% plus federal NIIT at 3.8%. On a $15M exit, the total tax difference between year 4 and year 5 exceeds $1.3 million — with $149,126 in NC income tax at year 4 on the non-excluded portion alone. If a transaction timeline allows any flexibility, reaching the 5-year mark is a dominant planning constraint for post-OBBBA stock.

4. Plan gifting and trust strategies before any transaction is signed

NC's conformity to §1202 applies at the donee level under §1202(h)(2). A North Carolina-resident family member or an irrevocable non-grantor trust that receives gifted QSBS shares has its own §1202 exclusion cap — up to $15M post-OBBBA — for the same shares. A founder with a $45M qualifying QSBS gain who gifts shares to two NC-resident family members before signing a definitive agreement can potentially triple the available exclusion. The gift must occur before any binding obligation to sell. For founders with exits substantially above $15M, trust structures sited in zero-income-tax states may provide additional savings on the non-QSBS portion of post-exit income — but QSBS trust strategy requires careful timing and legal coordination. See the gifting and stacking guide and the trusts guide.

5. Track North Carolina's conformity date for future federal §1202 changes

Under NC's static conformity regime, any Congressional amendment to §1202 enacted after July 5, 2025 will not automatically apply in North Carolina. If Congress makes additional §1202 changes — a further increase to the exclusion cap, changes to holding period rules, or new restrictions — those changes will not affect North Carolina until the General Assembly advances the conformity date. Founders with stock issued under future federal §1202 amendments should verify NC's current conformity date before relying on those rules at the state level.

6. Do not let the future rate cut drive hold decisions

NC's scheduled rate reduction from 3.99% to 3.49% in 2027 will save a founder approximately $75,000 in state tax on a $15M qualifying exit — less than 13% of the state tax savings from the §1202 exclusion itself. Do not delay a qualifying exit, a gifting transaction, or §1045 rollover planning specifically to wait for a lower NC rate. The federal holding period clock and the §1202 qualification window should drive timing decisions; state rate arbitrage is a second-order consideration at these dollar amounts.

Talk to a QSBS advisor about your North Carolina situation

NC SB 595's July 5, 2025 conformity date captures OBBBA's §1202 enhancements cleanly — but the §1202(e)(3) excluded-industry questions for RTP pharma/biotech and Charlotte fintech founders, the federal qualification tests, the OBBBA tiered holding period rules, and the gifting and trust planning window before a transaction all require professional review. A fee-only financial advisor who specializes in QSBS and founder liquidity can confirm qualification, model the full federal-plus-NC tax picture, and coordinate the pre-transaction planning window before the exclusion opportunity closes.

Fee-only focus - No obligation - Privacy-minded matching - Built for seven-figure planning decisions